Group 1 - The core business of Shanghai Lanwei Medical Laboratory Co., Ltd. is to provide third-party medical testing and pathological diagnosis services to various medical institutions, as well as sales of in vitro diagnostic products and other professional technical support [1] - As of the first quarter of 2025, the company reported a revenue of 351 million yuan, a year-on-year decrease of 19.60%, and a net profit of -8.08 million yuan, a year-on-year decrease of 854.01%, with a gross profit margin of 19.95% [1] - The latest closing price of Lanwei Medical is 9.39 yuan, down 1.26%, with a price-to-book ratio of 2.28 and a total market value of 3.761 billion yuan [1] Group 2 - The company is among four institutions holding shares, with a total of 186.16 million shares valued at 1.806 billion yuan [1] - The industry average price-to-earnings (PE) ratio is 49.65, while the median is 36.03, indicating that Lanwei Medical's PE ratio of -31.71 is significantly lower than the industry average [2] - The total market value of the industry is 106.53 billion yuan, with Lanwei Medical's market value being relatively small at 3.761 billion yuan [2]
兰卫医学收盘下跌1.26%，最新市净率2.28，总市值37.61亿元